Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg6,D-Trp79, NmePhe8]-substance P (6-II)-induced growth inhibition

British Journal of Cancer

Volumn 88, Issue 11, 2003, Pages 1808-1816

  Waters, C M ^a   MacKinnon, A C ^a   Cummings, J ^b   Tufail Hanif, U ^a   Jodrell, D ^b   Haslett, C ^a   Sethi, T ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Gastrin releasing peptide; SP G; Substance P analogues; Tumour growth

Indexed keywords

ADRENALIN; ANGIOTENSIN I; ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA ENDORPHIN; BOMBESIN; BRADYKININ; BRADYKININ RECEPTOR; CALCITONIN; CARBACHOL; CHOLECYSTOKININ; CHORIONIC GONADOTROPIN; CORTICOTROPIN; DYNORPHIN; ENDOTHELIN; GALANIN; GASTRIN RECEPTOR; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; GROWTH HORMONE RELEASING FACTOR; NEUROMEDIN B; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NEUROTENSIN; SUBSTANCE P; SUBSTANCE P [6-11] DERIVATIVE; SUBSTANCE P [6-11][6 ARGININE 7,9 DEXTRO TRYPTOPHAN 8 N METHYLPHENYLALANINE]; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER RESISTANCE; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; FEMALE; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MITOGENICITY; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; TUMOR BIOPSY; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BRADYKININ; CALCIUM; CARCINOMA, SMALL CELL; CELL DIVISION; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FIBROBLASTS; GASTRIN-RELEASING PEPTIDE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; PEPTIDE FRAGMENTS; RATS; RECEPTORS, BOMBESIN; RECEPTORS, NEUROPEPTIDE; SUBSTANCE P; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASOPRESSINS;

EID: 0037872259     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600957     Document Type: Article

References (34)

1. Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J (1996) Bombesin specifically induces intracellular calcium mobilisation via gastrin-releasing peptide receptors in human prostate cancer cells. J Mol Endocrinol 16: 297-306
2. Bepler G, Bading H, Heimann B, Kiefer P, Havemann K, Moelling K (1989) Expression of p64c-myc and neuroendocrine properties define three subclasses of small cell lung cancer. Oncogene 4: 45-50
3. Berendsen HH, de-Leiji L, de Vries EG, Mesander G, Mulder NH, De-Jong B, Postmus PE, Poppema S, Sluiter HJ, The TH (1988) Clinical characterisation of three small cell lung cancer cell lines established from one patient during longitudinal follow up. Cancer Res 48: 6891-6899
4. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M (i989) Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 63: 1714-1720
5. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE (1981) Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 41: 1751-1756
6. Bunn PAJ, Chan D, Dienhart DG, Tolley R, Tagawa M, Jewett PB (1992) Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity. Cancer Res 52: 24-31
7. Charlesworth A, Broad S, Rozengurt E (1996) The bombesin/GRP receptor transfected into Rat-1 fibroblasts couples to phospholipase C activation, tyrosine phosphorylation of p125FAK and paxillin and cell proliferation. Oncogene 12: 1337-1345
8. Chaudry A, Carrasquillo JA, Avis IL, Shuke N, Reynolds JC, Bartholomew R, Larson SM, Cuttitta F, Johnson BE, Mulshine JL (1999) Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res 5: 3385-3393
9. Clive S, Webb DJ, MacLellan A, Young A, Byrne B, Robson L, Smyth JF, Jodrell DI (2001) Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist. Clin Cancer Res 10: 3071-3078
10. mePhe8]-substance P(6-11) in nude mice bearing the H69 small-cell lung cancer xenograft. Ann Oncol 6: 595-602
11. de Vries EG, Meijer CJ, Timmer BH, Berendsen HH, Mulder NH (1989) Resistance mechanisms in three SCLC cell lines established from one patient during clinical follow up. Cancer Res 49: 4175-7178
12. Ferris HA, Carroll RE, Rasenick MM, Benya RV (1997) Constitutive activation of the gastrin-releasing peptide receptor expressed by the non-malignant human colon epithelial cell line NCM460. J CIin Invest 100: 2530-2537
13. Fogh J, Fogh JM, Orfeo T (1977) One hundred and twenty-seven cultured human tumour cell lines producing tumours in nude mice. J Natl Cancer Inst 59: 221-226
14. Halmos G, Wittliff JL, Schally AV (1995) Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 55: 280-287
15. Hay FG, Duncan LW, Leonard RC (1991) Establishment and characterisation of two new small cell lung cancer cell lines-one from a patient with previous familial retinoblastoma. Br J Cancer 14 (Suppl): 43-45
16. 11]Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J Biol Chem 273: 3097-3104
17. Jensen R, Jones SW, Folkers K, Gardner JD (1984) A synthetic peptide that is a bombesin receptor antagonist. Nature 309: 61-63
18. 11]substance P in xenograft bearing Nu/Nu mice. Peptides 18: 1073-1077
19. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RC, Smyth JF (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 48: 6166-6172
20. Langdon S, Sethi T, Ritchie A, Muir M, Smyth J, Rozengurt E (1992) Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res 52: 4554-4557
21. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G (1975) Establishment of a continuous tumour-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 15: 741-747
22. 8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism. Br J Cancer 80: 1026-1034
23. MacKinnon AC, Waters C, Jodrell D, Haslett C, Sethi T (2001) Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism. J Biol Chem 276: 28083-28091
24. Moody TW, Carney DN, Cuttitta F, Quattrocchi K, Minna JD (1985) High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. Life Sci 37: 105-113
25. North WG, Fay MJ, Longo K, Du J (1997) Functional vasopressin V1 type receptors are present in variant as well as classical forms of small-cell carcinoma. Peptides 18: 985-993
26. Reubi JC, Schaer JC, Waser B (1997) Cholecystokinin(CCK)-A and CCK-B/ gastrin receptors in human tumours. Cancer Res 57: 1377-1386
27. O'Hara BM, Oskarsson M, Tainsky MA, Blair DG (1986) Mechanism of activation of human ras genes cloned from a gastric adenocarcinoma and a pancreatic carcinoma cell line. Cancer Res 46: 4695-4700
28. Seckl MJ, Newman RH, Freemont PS, Rozengurt E (1995) Substance P-related antagonists inhibit vasopressin and bombesin but not 5′-3-O-(thio)triphosphate-stimulated inositol phosphate production in Swiss 3T3 cells. J Cell Physiol 163: 87-95
29. 2+ mobilisation and clonal growth. Cancer Res 53: 5208-5213
30. Sethi T, Langdon S, Smythe J, Rozengurt E (1992) Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum neuropeptides antagonists in vitro and in vivo. Cancer Res 52: 27375-27425
31. Sethi T, Rozengurt E (1991) Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin and neurotensin. Cancer Res 51: 3621-3623
32. Stark LA, Din FVN, Zwacka RM, Dunlop MG (2001) Aspirin-induced activation of the NF-κB signalling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 15: 1273-1275
33. Tallett A, Chilvers ER, MacKinnon AC, Haslett C, Sethi T (1996) Neuropeptides stimulate tyrosine phosphorylation and tyrosine kinase activity in small cell lung cancer cell lines. Peptides 17: 665-673
34. Woll PJ, Rozengurt E (1988) Two classes of antagonist interact with receptors for the mitogenic neuropeptides bombesin, bradykinin, and vasopressin. Growth Factors 1: 75-83